Skip to content
Search

Latest Stories

Rajkummar Rao starrer Chupke Chupke remake to start rolling in March 2021

Murtuza Iqbal

Rajkummar Rao is undoubtedly one of the busiest actors in Bollywood. He is currently gearing up for the direct-to-digital release of his two films Ludo (Netflix) and Chhalaang (Amazon Prime Video) and has four other films lined-up.


One of the upcoming films of Rao is the remake of Chupke Chupke. The original film starred Dharmendra, Sharmila Tagore, Amitabh Bachchan, and Jaya Bachchan. The actor will be stepping into the shoes of Dharmendra for the remake and according to a report in Mumbai Mirror, the shooting of the film will kickstart in March 2021.

A source told the tabloid, “The script is undergoing some rewrites as the makers are determined to do justice to the original. They are also in talks with several actors for the role of Sukumar, professor of English masquerading as Parimal, and trying to teach botany, enacted by Amitabh Bachchan in the original. The cast should be locked by December.”

Meanwhile, Rao is all set to start shooting for his next untitled film with Kriti Sanon. The movie goes on the floors this week in Chandigarh. The source stated, “He flies to Chandigarh today with the entire team. It’s a marathon schedule, to be shot at real locations, and will continue till the year-end.”

Well, apart from Chupke Chupke remake and the untitled film with Kriti, Rao has movies like Badhaai Do and the remake of Telugu film Hit in his kitty. While Badhaai Do starts rolling in January next year, Hit remake might go on the floors by end of April or in May.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less